Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00286637 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Novel Glaucoma Diagnostics

StatusRecruiting
PhaseNot specified
SponsorWills Eye
Started
View on ClinicalTrials.gov ↗

Record History

  1. Lead sponsor: NYU Langone Health to Wills Eye Enrollment target: 1322 to 5000 · Primary completion date: Aug 10, 2023 to Jul 31, 2029 · Start date: Jan 1995 to Aug 1, 2000 · 4 morev21 Show all 8 changesShow less
    • Enrollment target: 1322 to 5000
    • Primary completion date: Aug 10, 2023 to Jul 31, 2029
    • Start date: Jan 1995 to Aug 1, 2000
    • Trial status: Completed to Recruiting
    • Completion date: Feb 19, 2024 to Jul 31, 2029
    • Study site revised
    • Study title shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  2. Primary endpoint revised Eligibility criteria expanded, about 72 words · Study description expanded, about 24 wordsv20 Show all 3 changesShow less
    • Eligibility criteria expanded, about 72 words
    • Study description expanded, about 24 words

    See this version in full on ClinicalTrials.gov ↗

  3. Trial status: Recruiting to Completed Enrollment target: estimated 2767 to confirmed 1322 · Primary completion date changed from estimate of Jan 2024 to Aug 10, 2023 · Study completion date changed from estimate of Jan 2025 to Feb 19, 2024 · 1 morev19 Show all 5 changesShow less
    • Enrollment target: estimated 2767 to confirmed 1322
    • Primary completion date changed from estimate of Jan 2024 to Aug 10, 2023
    • Study completion date changed from estimate of Jan 2025 to Feb 19, 2024
    • Site details revised
  4. Re-verified, no change to tracked fieldsv18
  5. Site contact updatedv17
Show 15 earlier versionsHide 15 earlier versions
  1. 2 versions Re-verified since Jul 12, 2021, no change to tracked fieldsv15-v16
  2. Primary completion date: Jan 2020 to Jan 2024 Completion date: Jan 2020 to Jan 2025v14 Show all 2 changesShow less
    • Completion date: Jan 2020 to Jan 2025
  3. Trial status: Active, Not Recruiting to Recruiting Site details revisedv13 Show all 2 changesShow less
    • Site details revised
  4. Primary completion date: May 2018 to Jan 2020v12
  5. Primary completion date: Jan 2018 to May 2018 Study site revisedv11 Show all 2 changesShow less
    • Study site revised

    See this version in full on ClinicalTrials.gov ↗

  6. Re-verified, no change to tracked fieldsv10
  7. Lead sponsor: University of Pittsburgh to NYU Langone Health Primary completion date: May 2017 to Jan 2018 · Trial status: Recruiting to Active, Not Recruiting · Enrollment target: estimated 500 to confirmed 2767 · 4 morev9 Show all 8 changesShow less
    • Primary completion date: May 2017 to Jan 2018
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 500 to confirmed 2767
    • Completion date: Jun 2017 to Jan 2020
    • Study description expanded, about 498 words
    • Site details revised
    • Collaborator revised

    See this version in full on ClinicalTrials.gov ↗

  8. Re-verified, no change to tracked fieldsv8
  9. Primary completion date: May 2012 to May 2017 Completion date: May 2012 to Jun 2017v7 Show all 2 changesShow less
    • Completion date: May 2012 to Jun 2017
  10. Primary and study completion dates: May 2012 Site contact updatedv6 Show all 2 changesShow less
    • Site contact updated
  11. Re-verified, no change to tracked fieldsv5
  12. Eligibility criteria shortened, about 6 words Site contact updatedv4 Show all 2 changesShow less
    • Site contact updated

    See this version in full on ClinicalTrials.gov ↗

  13. 2 versions Re-verified since Sep 8, 2006, no change to tracked fieldsv2-v3
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Wills Eye
5 trials monitored
See 1 trial at risk
The purpose of this research is to evaluate novel technologies for the assessment of ocular structure and function, including the scanning device called Optical Coherence Tomography (OCT). We will test the OCT and other devices in their ability to image diseases of the eye and also compare the measurements made with OCT to those of other imaging and visual field devices approved by the Food and Drug Administration (FDA). OCT may be useful for the early diagnosis and monitoring of a variety of types of eye diseases
Trial Details
NCT Number NCT00286637
Lead Sponsor Wills Eye
Collaborators: National Eye Institute (NEI)
Conditions Glaucoma, Macular Disease
Enrollment 5,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov